|Statut :||Clos aux inclusions|
|Étape du traitement :||Traitements combinés|
|Date d'ouverture :||23/06/2017|
|Date clôture :||01/01/2024|
|Promoteur :||Seagen Inc.|
|Progression du cancer:||Loco-régional et à distance|
This trial studies how well the drug tucatinib works when given with trastuzumab and when given by itself. The participants in this trial have HER2-positive (HER2+) metastatic colorectal cancer (mCRC). 'Metastatic' means that the cancer has spread to other parts of the body.
In the first part of this study, participants enrolled into Cohort A and received both tucatinib and trastuzumab. In the second part of this study, participants are randomly assigned to either Cohort B or Cohort C. Participants in Cohort B will receive tucatinib and trastuzumab. Participants in Cohort C will receive tucatinib. Participants in Cohort C who do not respond to therapy may have an option to receive tucatinib plus trastuzumab.
- Cancers digestifs
- Tumeur maligne du côlon - Cim10 : C18
- Tumeur maligne du rectum - Cim10 : C20